The discoveries that pasireotide stimulates SSTR1 more than SSTR2 and that it has a 30‐ to 40‐fold higher affinity for SSTR1 than octreotide may allow pasireotide to be used as a treatment option; however, there is currently no clinical data on the treatment effect of pasireotide on dominantly SSTR1 expressing tumours (Bruns et al., 2002; Iacovazzo et al., 2016). The gene discussed is SSTR2; the disease is neoplasm.